Canopy Growth demonstrated solid financial progress in Q3 FY2026, achieving its narrowest adjusted EBITDA loss to date while simultaneously enhancing its balance sheet and operational efficiency. The company is well-positioned for future growth, particularly in medical cannabis and international markets.
- Adjusted EBITDA loss narrowed significantly, reflecting ongoing cost discipline and improved execution.
- Canadian medical revenue increased by 15% year-over-year, marking the sixth consecutive quarter of growth.
- The planned acquisition of MTL Cannabis aims to strengthen Canopy's leadership in Canadian medical cannabis and expand its presence in Quebec's adult-use market.
- Net revenue from international operations increased by 22% sequentially, indicating positive momentum in global markets.
- A recapitalization effort successfully bolstered liquidity, extending debt maturities to 2031 and enhancing financial flexibility.
Community Discussion